MedTrace Logo

Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy

NCT01606722 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2013-07-11

No results posted yet for this study

Summary

To evaluate the relationship between plasma and intracellular darunavir (DRV) concentrations and virological efficacy in HIV-infected patients on DRV/rtv monotherapy.

Conditions

  • HIV-infection

Interventions

DRUG

Darunavir/ritonavir

Darunavir/ritonavir (800/100 mg once daily) monotherapy

Sponsors & Collaborators

  • Hospitales Universitarios Virgen del Rocío

    lead OTHER

Principal Investigators

  • Luis F Lopez-Cortes, MD, PhD. · Hospital Universitario Virgen del Rocio. Sevilla. Spain

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01606722 on ClinicalTrials.gov